VERAPAMIL ( DrugBank: Verapamil )


4 diseases
告示番号疾患名(ページ内リンク)臨床試験数
58肥大型心筋症2
96クローン病1
140ドラベ症候群1
167マルファン症候群2

58. 肥大型心筋症


臨床試験数 : 126 薬物数 : 135 - (DrugBank : 42) / 標的遺伝子数 : 46 - 標的パスウェイ数 : 162
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05569382
(ClinicalTrials.gov)
August 10, 20224/10/2022Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic CardiomyopathyTreatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic CardiomyopathyNon-obstructive Hypertrophic CardiomyopathyDrug: Verapamil;Drug: Bisoprolol;Drug: PlaceboMorten Steen Kvistholm JensenBispebjerg Hospital;Rigshospitalet, Denmark;Viborg Regional Hospital;Zealand University Hospital;Odense University Hospital;Gentofte University HospitalRecruiting18 YearsN/AAll140Phase 4Denmark
2EUCTR2021-006953-77-DK
(EUCTR)
11/04/202231/01/2022The effect of Bisoprolol and Verapamil in non-obstructive hypertrophic cardiomyopathyTreatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathy - TEMPO II Non-obstructive Hypertrophic cardiomyopathy
MedDRA version: 20.0;Level: PT;Classification code 10007636;Term: Cardiomyopathy;System Organ Class: 10007541 - Cardiac disorders
MedDRA version: 20.0;Classification code 10049813;Term: Non-obstructive cardiomyopathy;Classification code 10020871;Term: Hypertrophic cardiomyopathy;System Organ Class: 10010331 - Congenital, familial and genetic disorders
MedDRA version: 20.0;Level: LLT;Classification code 10061029;Term: Cardiomyopathy primary;System Organ Class: 10007541 - Cardiac disorders;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Trade Name: Bisoprolol
INN or Proposed INN: BISOPROLOL
Trade Name: Isoptin
INN or Proposed INN: VERAPAMIL HYDROCHLORIDE
Aarhus University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Phase 2Denmark

96. クローン病


臨床試験数 : 2,442 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01261286
(ClinicalTrials.gov)
August 201014/12/2010Drug-Disease Interaction in Crohn's DiseasePharmacodynamics and Pharmacokinetics of Verapamil in Crohn's Disease PatientsCrohn's DiseaseDrug: verapamilUniversity of AlbertaNULLCompleted18 Years65 YearsBothPhase 1Canada

140. ドラベ症候群


臨床試験数 : 116 薬物数 : 65 - (DrugBank : 17) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 64
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01607073
(ClinicalTrials.gov)
April 201224/5/2012Verapamil as Therapy for Children and Young Adults With Dravet SyndromeVerapamil as Adjunctive Seizure Therapy for Children and Young Adults With Dravet SyndromeDravet SyndromeDrug: VerapamilGillette Children's Specialty HealthcareMayo Clinic;Ann & Robert H Lurie Children's Hospital of Chicago;Dartmouth-Hitchcock Medical CenterCompleted2 Years25 YearsAll2Phase 2United States

167. マルファン症候群


臨床試験数 : 21 薬物数 : 40 - (DrugBank : 11) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 50
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01295047
(ClinicalTrials.gov)
July 200611/2/2011Comparison of Medical Therapies in Marfan Syndrome.Effects of Atenolol, Perindopril and Verapamil on Haemodynamic and Vascular Function in Marfan Syndrome - A Randomised Double-Blind Crossover TrialMarfan SyndromeDrug: Atenolol;Drug: VERAPAMIL;Drug: PerindoprilCardiff UniversityNULLCompleted16 Years60 YearsBoth18Phase 4United Kingdom
2EUCTR2005-000749-13-GB
(EUCTR)
30/07/200520/06/2005 A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. A Randomised Double-Blind Trial of Medical Treatment In Marfan Syndrome. Marfan SyndromeTrade Name: Atenolol
Product Name: Atenolol
Product Code: N/A
INN or Proposed INN: N/A
Other descriptive name: N/A
Trade Name: Coversyl
Product Name: Coversyl
Product Code: N/A
INN or Proposed INN: N/A
Other descriptive name: PERINDOPRIL
Trade Name: Verapamil
Product Name: Verapamil SR
Product Code: N/A
INN or Proposed INN: N/A
Other descriptive name: N/A
Cardiff UniversityNULLNot Recruiting Female: yes
Male: yes
60 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yesUnited Kingdom